Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
25 hedge funds and large institutions have $13.3M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
1,000% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 1
67% more funds holding
Funds holding: 15 → 25 (+10)
30% more capital invested
Capital invested by funds: $10.2M → $13.3M (+$3.09M)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
+$945K |
| 2 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$467K |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$336K |
| 4 |
ACA
Apis Capital Advisors
New York
|
+$237K |
| 5 |
Renaissance Technologies
New York
|
+$212K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$272K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$254K |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$191K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$19.4K |
| 5 |
BlackRock
New York
|
-$3.12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| – | +$418 | +30 | New |
|
OPNT Hedge Fund Activity: Q3 2019 in Review
25 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q3 2019, worth a combined $13.3M — up 30% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new OPNT positions and 1 closed out — a net gain of 10 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Fondren Management, adding an estimated $945K. The largest seller was Morgan Stanley, cutting an estimated $272K.
- 25 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q3 2019, up from 15 in Q2 2019.
- Funds reported $13.3M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q3 2019, up 30% quarter-over-quarter.
- 11 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 1 closed out, a net change of +10 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Fondren Management, an estimated $945K added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Morgan Stanley, an estimated $272K sold.
Based on aggregated 13F filings for Q3 2019.